Australia markets closed

Vectus Biosystems Limited (VBS.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.44000.0000 (0.00%)
At close: 03:59PM AEDT

Vectus Biosystems Limited

3-11 Primrose Avenue
Rosebery, NSW 2018
61 2 9381 1000

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Karen Annette DugganCEO & Exec. Director229.93kN/AN/A
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFinCompany Sec.N/AN/AN/A
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.ConsultantN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.

Corporate governance

Vectus Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.